Matrix Capital Management Company’s Adaptimmune Therapeutics ADAP Stock Holding History

Matrix Capital Management Company’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-37,681,515	Closed	-$35.8M	–	6
2024 Q3	$35.8M	Sell	37,681,515 -1,292,670	-3%	-$1.47M	1.71%	6
2024 Q2	$38M	Hold	38,974,185	–	–	0.29%	20
2024 Q1	$61.6M	Hold	38,974,185	–	–	0.57%	15
2023 Q4	$30.9M	Hold	38,974,185	–	–	0.32%	17
2023 Q3	$30.4M	Hold	38,974,185	–	–	0.36%	17
2023 Q2	$36.1M	Hold	38,974,185	–	–	0.42%	16
2023 Q1	$42.5M	Hold	38,974,185	–	–	0.58%	15
2022 Q4	$56.9M	Hold	38,974,185	–	–	1.09%	14
2022 Q3	$41.9M	Hold	38,974,185	–	–	0.8%	19
2022 Q2	$66.3M	Hold	38,974,185	–	–	1.5%	14
2022 Q1	$80.3M	Hold	38,974,185	–	–	0.96%	21
2021 Q4	$146M	Hold	38,974,185	–	–	1.63%	16
2021 Q3	$201M	Hold	38,974,185	–	–	2.29%	17
2021 Q2	$166M	Hold	38,974,185	–	–	1.81%	18
2021 Q1	$207M	Hold	38,974,185	–	–	2.39%	16
2020 Q4	$210M	Hold	38,974,185	–	–	2.27%	17
2020 Q3	$311M	Hold	38,974,185	–	–	4.13%	10
2020 Q2	$390M	Buy	38,974,185 +4,545,455	+13%	+$28.5M	6.08%	7
2020 Q1	$93.6M	Buy	34,428,730 +6,428,730	+23%	+$21.3M	2.39%	15
2019 Q4	$33.6M	Hold	28,000,000	–	–	0.72%	19
2019 Q3	$42.3M	Hold	28,000,000	–	–	1.04%	16
2019 Q2	$113M	Hold	28,000,000	–	–	2.08%	17
2019 Q1	$120M	Buy	28,000,000 +851,000	+3%	+$3.96M	3.21%	12
2018 Q4	$156M	Buy	27,149,000 +6,786,989	+33%	+$50.1M	5.17%	8
2018 Q3	$276M	Buy	20,362,011 +6,278,500	+45%	+$65.8M	6.82%	5
2018 Q2	$167M	Buy	14,083,511 +201,500	+1%	+$2.51M	4.75%	8
2018 Q1	$156M	Buy	13,882,011 +1,668,500	+14%	+$14.6M	5.42%	8
2017 Q4	$81.6M	Buy	12,213,511 +170,000	+1%	+$1.31M	2.91%	12
2017 Q3	$98.6M	Buy	12,043,511 +3,351,428	+39%	+$20.9M	3.15%	13
2017 Q2	$39M	Buy	+8,692,083	New	+$45.4M	1.33%	16

Other funds holding ADAP

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Matrix Capital Management Company's ADAP Position: Q4 2024 in Review

Matrix Capital Management Company sold out of Adaptimmune Therapeutics (ADAP) in Q4 2024, closing a stake of 37,681,515 shares — an estimated $35.8M sold.

Matrix Capital Management Company first reported a position in ADAP in Q2 2017 and held it in 30 quarters. The position peaked at $390M in Q2 2020. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2024.

Matrix Capital Management Company reported no remaining Adaptimmune Therapeutics position as of Q4 2024 after selling out during the quarter.
Matrix Capital Management Company sold 37,681,515 Adaptimmune Therapeutics shares in Q4 2024, an estimated $35.8M.
Matrix Capital Management Company first reported a position in Adaptimmune Therapeutics in Q2 2017 and held it in 30 quarters.
Matrix Capital Management Company's Adaptimmune Therapeutics position peaked at $390M in Q2 2020.
80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2024.

Based on Matrix Capital Management Company's 13F filing for Q4 2024, filed 13 Feb 2025.